Qvanteq AG today announced that it has enrolled the first patient in the First in Man (FiM) clinical study QUEST I, this is following earlier regulatory approval from the Dutch and Swiss authorities. The aim of the QUEST I study is to assess feasibility and safety of the Qstent, a bioactive, coating-free coronary stent. The […]
Qvanteq was amongst the “Top 100 Swiss Startups” for the 4th time in a row.
Qvanteq won the CTI best poster award. Read more
A portrait of Qvanteq AG was published in the the Swiss business journal “Handelszeitung” under the the title “Am Puls des Herzens”. Full article (g).